Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec 10.
doi: 10.1002/oby.70120. Online ahead of print.

Real-World Evidence on Weight Loss and Safety With Semaglutide in Obesity Telehealth: A Large Retrospective Cohort Study

Beverly Tchang  1   2 , Lauren Broffman  2 , Raoul Manalac  2 , Sam Chai  2 , Nicholas Samonas  2 , Melynda Barnes  2 , David B Allison  2   3
Affiliations

Real-World Evidence on Weight Loss and Safety With Semaglutide in Obesity Telehealth: A Large Retrospective Cohort Study

Beverly Tchang et al. Obesity (Silver Spring). .

Abstract

Objective: This study aimed to assess weight and safety outcomes in a large national cohort of patients with overweight and obesity treated with GLP-1 medications via telehealth.

Methods: Data were obtained from deidentified EHRs for a random sample of 4500 patients who initiated semaglutide treatment via telehealth for overweight and obesity between December 1, 2022, and June 1, 2023. Outcomes and predictors of outcomes were analyzed for patients who reported a follow-up weight within ±14 days of week 68.

Results: Of 655 patients (n = 445 female, n = 210 male), mean body weight reduction was -16.6% (SD 7.5%, 95% CI: -17.1% to -16.0%). Female sex was the only factor consistently associated with categorical weight loss, with significantly higher odds at ≥ 5% (OR 4.26, p < 0.001), ≥ 10% (OR 5.90, p < 0.001), and ≥ 20% (OR 2.51, p < 0.001). The most common adverse events were nausea/vomiting (37.3%) and constipation (15.6%); no new safety signals were observed.

Conclusions: Findings suggest semaglutide treatment via telehealth can achieve trial-level weight loss with similar safety profiles, supporting telehealth as an evidence-based approach to medical weight management.

Keywords: antiobesity; glucagon‐like peptide‐1 (GLP‐1); pharmacologic therapy; treatment outcomes.

PubMed Disclaimer

References

    1. H. Al Hennawi, M. Zohaib, M. K. Khan, et al., “Temporal Trends in Obesity‐Related Mortality Rates: An Analysis of Gender, Race/Ethnicity, and Geographic Disparities in the United States,” Current Problems in Cardiology 49, no. 1 Pt C (2024): 102108, https://doi.org/10.1016/j.cpcardiol.2023.102108.
    1. O. Al Ta'ani, Y. A. Al‐Ajlouni, W. Aleyadeh, et al., “The Impact of Overweight and Obesity on Health Outcomes in the United States From 1990 to 2021,” Diabetes, Obesity & Metabolism 26, no. 11 (2024): 5455–5465, https://doi.org/10.1111/dom.15924.
    1. J. P. H. Wilding, R. L. Batterham, S. Calanna, et al., “Once‐Weekly Semaglutide in Adults With Overweight or Obesity,” New England Journal of Medicine 384, no. 11 (2021): 989–1002, https://doi.org/10.1056/NEJMoa2032183.
    1. H. Gasoyan, W. S. Butsch, R. Schulte, et al., “Changes in Weight and Glycemic Control Following Obesity Treatment With Semaglutide or Tirzepatide by Discontinuation Status,” Obesity 33 (2025): 1657–1667, https://doi.org/10.1002/oby.24331.
    1. W. Ghusn, S. Fansa, D. Anazco, et al., “Weight Loss and Cardiovascular Disease Risk Outcomes of Semaglutide: A One‐Year Multicentered Study,” International Journal of Obesity 48, no. 5 (2024): 662–667, https://doi.org/10.1038/s41366‐023‐01456‐5.

LinkOut - more resources